Vaccines, hygienist Calabrò: "Anti-RSV is a public health investment and a weapon against antibiotic resistance."

HTA study at a hygienists' conference: "Highly significant results in terms of avoided cases and reduced economic impact on the National Health Service."

"Vaccinating adults and the elderly against respiratory syncytial virus (RSV) not only reduces direct healthcare costs, but also represents a concrete tool for combating antimicrobial resistance (AMR)." This was stated by Giovanna Elisa Calabrò, professor of Hygiene and Public Health at the University of Cassino and Southern Lazio, today in Bologna during the 58th National Congress of the Italian Society of Hygiene (SITI). Calabrò noted that the research group she coordinates has already published a Health Technology Assessment (HTA) on the recombinant adjuvanted RSV vaccine for adults, with "very significant results in terms of cases avoided and positive economic impact on the healthcare system."

Vaccination "in the vulnerable adult population," the specialist emphasizes, "cannot be evaluated solely for its direct clinical effect, but also for its overall social value. Reducing the inappropriate use of antibiotics means contributing to the global fight against antibiotic resistance." For Calabrò, "every dose administered is also a step forward toward a more sustainable use of healthcare resources and an integrated prevention model."